The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Cannabis and psychosis/schizophrenia: human studies
Open accessAbstract
The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. The mechanisms by which cannabinoids produce transient psychotic symptoms, while unclear may involve dopamine, GABA, and glutamate neurotransmission. However, only a very small proportion of the general population exposed to cannabinoids develop a psychotic illness. It is likely that cannabis exposure is a “component cause” that interacts with other factors to “cause” schizophrenia or a psychotic disorder, but is neither necessary nor sufficient to do so alone. Nevertheless, in the absence of known causes of schizophrenia, the role of component causes remains important and warrants further study. Dose, duration of exposure, and the age of first exposure to cannabinoids may be important factors, and genetic factors that interact with cannabinoid exposure to moderate or amplify the risk of a psychotic disorder are beginning to be elucidated. The mechanisms by which exposure to cannabinoids increase the risk for developing a psychotic disorder are unknown. However, novel hypotheses including the role of cannabinoids on neurodevelopmental processes relevant to psychotic disorders are being studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–234 of 234
Cannabis-Induced Psychotic-Like Experiences Are Predicted by High Schizotypy
Stirling, J., Barkus, E., Nabosi, L., Irshad, S., Roemer, G., Schreudergoidheijt, B., & Lewis, S. W. (2008) · Psychopathology · doi:10.1159/000155215 · Cited by 69
Rubino, T., Viganò, D., Premoli, F., Castiglioni, C., Bianchessi, S., Zippel, R., & Parolaro, D. (2006) · Molecular Neurobiology · doi:10.1385/mn:33:3:199 · Cited by 69
Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential
Johnson, J. P., Muhleman, D. R., MacMurray, J. P., Gade, R., Verde, R., Ask, M., Kelley, J., & Comings, D. E. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000246 · Cited by 69
González, R., Carey, C. L., & Grant, I. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb06003.x · Cited by 66
Marijuana and memory impairment: Effect on free recall and recognition memory
Miller, L. L., McFarland, D. J., Cornett, T., & Brightwell, D. R. (1977) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(77)90191-5 · Cited by 62
Psychosis after cannabis abuse.
Carney, M. W. P., BACELLE, L., & Robinson, B. M. (1984) · BMJ · doi:10.1136/bmj.288.6423.1047 · Cited by 59
Ponce, G., Hoenicka, J., Rubio, G., Ampuero, I., Jiménez‐Arriero, M. Á., Rodríguez–Jiménez, R., Palomo, T., & Ramos, J. A. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001278 · Cited by 58
No association of CNR1 gene variations with susceptibility to schizophrenia
Seifert, J., Ossege, S., Emrich, H. M., Schneider, U., & Stuhrmann, M. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.08.008 · Cited by 57
A retrospective study of symptom patterns of cannabis‐induced psychosis
Imade, G. T., & Ebie, J. C. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb07378.x · Cited by 55
Sneider, J. T., Pope, H. G., Silveri, M. M., Simpson, N. S., Gruber, S. A., & Yurgelun-Todd, D. A. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.04.016 · Cited by 51
Cannabis use and genetic predisposition for schizophrenia: a case-control study
Veling, W., Mackenbach, J. P., van Os, J., & Hoek, H. W. (2008) · Psychological Medicine · doi:10.1017/s0033291708003474 · Cited by 51
Hollister, L. E. (1988) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1988.tb08576.x · Cited by 47
Duan, J., Martinez, M. M., Sanders, A. R., Hou, C., Krasner, A., SCHWARTZ, D. B., & Gejman, P. V. (2005) · Psychological Medicine · doi:10.1017/s0033291705005428 · Cited by 46
Leweke, F. M., Kampmann, C., Radwan, M., Dietrich, D. E., Johannes, S., Emrich, H. M., & Münte, T. F. (1998) · Neuropsychobiology · doi:10.1159/000026487 · Cited by 44
Levonantradol for Chemotherapy‐Induced Emesis: Phase I—II Oral Administration
László, J., Lucas, V. S., Hanson, D., Cronin, C. M., & Sallan, S. E. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02573.x · Cited by 44
Reasons for Cannabis Use: Patients with Schizophrenia Versus Matched Healthy Controls
Schaub, M. P., Fanghaenel, K., & Stohler, R. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802512016 · Cited by 43
Angelucci, F., Ricci, V., Spalletta, G., Pomponi, M., Tonioni, F., Caltagirone, C., & Bria, P. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.008 · Cited by 43
Thacore, V. R. (1973) · The British Journal of Psychiatry · doi:10.1192/bjp.123.2.225 · Cited by 41
Cannabis and motor function: fMRI changes following 28 days of discontinuation.
Pillay, S. S., Rogowska, J., Kanayama, G., Gruber, S. A., Simpson, N. S., Pope, H. G., & Yurgelun-Todd, D. A. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.1.22 · Cited by 40
Hallucinogenic Effects of Marijuana as Currently Used
KEELER, M. H., Ewing, J. A., & Rouse, B. A. (1971) · American Journal of Psychiatry · doi:10.1176/ajp.128.2.213 · Cited by 39
Shiota, S., Tochigi, M., Shimada, H., Ohashi, J., Kasai, K., Kato, N., Tokunaga, K., & Sasaki, T. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0332-9 · Cited by 38
Spencer, D. J. (1971) · International Journal of the Addictions · doi:10.3109/10826087109057790 · Cited by 36
Miyamoto, A., Yamamoto, T., Ohno, M., Watanabe, S., Tanaka, H., Morimoto, S., & Shoyama, Y. (1996) · Brain Research · doi:10.1016/0006-8993(95)01352-0 · Cited by 36
Possible role of dopamine D1 receptors in schizophrenia
Okuba, Y., Suhara, T., Sudo, Y., & Toru, M. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000281 · Cited by 35
Failure to replicate the association between NRG1 and schizophrenia using Japanese large sample
Ikeda, M., Takahashi, N., Saito, S., Aleksić, B., Watanabe, Y., Nunokawa, A., Yamanouchi, Y., Kitajima, T., Kinoshita, Y., Kishi, T., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.010 · Cited by 33
The effects of cannabis use on the clinical condition of schizophrenics.
Negrete, J. C., & Knapp, W. P. (1986) · PsycEXTRA Dataset · doi:10.1037/e471282004-001 · Cited by 25
Schizotypy, marijuana, and differential item functioning
Earleywine, M. (2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.802 · Cited by 24
Citron, M. L., Ts, H., Vreeland, F., Krasnow, S. H., Fossieck, B. E., Harwood, S., Franklin, R., & Mh, C. (1985) · PubMed · Cited by 23
Metabolic studies of drugs of abuse.
Volkow, N. D., Fowler, J. S., Wolf, A. P., & Gillespi, H. (1990) · PubMed · Cited by 23
Maj, P. F., Collu, M., Fadda, P., Cattaneo, A., Racagni, G., & Riva, M. A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05565.x · Cited by 22
Stambaugh, J. E., McAdams, J., & Vreeland, F. (1984) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1984.tb02756.x · Cited by 22
Macleod, J. (2007) · Psychological Medicine · doi:10.1017/s0033291707000359 · Cited by 20
Heim, M. E., Quei�er, W., & Altenburg, H.-P. (1984) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257128 · Cited by 18
Marihuana induced hallucinations.
Mh, K. (1968) · PubMed · Cited by 17
Cited by
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
Seely, K. A., Lapoint, J., Moran, J. H., & Fattore, L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.017 · Cited by 465
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 462
Batalla, A., Bhattacharyya, S., Yücel, M., Fusar-Poli, P., Crippa, J. A., Nogué, S., Torrens, M., Pujol, J., Farré, M., & Martin-Santos, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055821 · Cited by 416
Toward a neurobiology of delusions
Corlett, P. R., Taylor, J. R., Wang, X.-J., Fletcher, P. C., & Krystal, J. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.007 · Cited by 394
Metadata
- Authors
- D’Souza, D. C., Sewell, R. A., & Ranganathan, M.
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2009-07-16
- Volume
- 259
- Issue
- 7
- Pages
- 413-431
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W2132835664
- Cited by
- 295
- References
- 234
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.